基于中国医院药物警戒系统开展药品不良反应监测研究

doi:10.19803/j.1672-8629.2020.10.05

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (10): 672-675.
DOI: 10.19803/j.1672-8629.2020.10.05

基于中国医院药物警戒系统开展药品不良反应监测研究

莫凯¹, 农莉¹, 曹雯², 钟慧¹, 王艳宁¹, 蓝晓步^1,*

¹南宁市第一人民医院,广西南宁 530022;
²广西国际壮医医院,广西南宁 530001

收稿日期:2020-10-14 修回日期:2020-10-14 出版日期:2020-10-15 发布日期:2020-10-13
通讯作者: ^*蓝晓步,男,博士,副主任药师,医院药学。E-mail：1317972754@qq.com
作者简介:莫凯,男,硕士,主管药师,临床药学。
基金资助:
广西壮族自治区卫生和计划生育委员会自筹经费科研课题（Z20170041）：基于循证药学及PDCA循环建立医院药物合理使用评价模式的研究

Research on Adverse Drug Reaction Monitoring Based on Chinese Hospital Pharmacovigilance System

MO Kai¹, NONG Li¹, CAO Wen², ZHONG Hui¹, WANG Yanning¹, LAN Xiaobu^1,*

¹The First People's Hospital of Nanning, Nanning Guangxi 530022, China;
²Guangxi International Zhuang Medicine Hospital, Nanning Guangxi 530001, China

Received:2020-10-14 Revised:2020-10-14 Online:2020-10-15 Published:2020-10-13

摘要/Abstract

摘要： 目的分析医院应用中国医院药物警戒系统开展药品不良反应监测的效果,为我国医疗机构开展药品不良反应监测工作提供参考。方法选取某院应用中国医院药物警戒系统前、后1年内报告的药品不良反应报告,统计分析2段时间内的报告情况及报告表填报质量,评价中国医院药物警戒系统的应用效果。结果应用中国医院药物警戒系统后,报告总数由60份上升至174份,药师主动监测报告总数由25份上升至99份,每份报告平均用时由35.39 min缩短至15.77 min,报告不合格率由40.63%下降至3.23%。结论中国医院药物警戒系统的建立与应用有效提高了医院药品不良反应监测管理水平,对进一步加强我国医院药物警戒工作具有重要意义。

关键词: 中国医院药物警戒系统, 药品不良反应

Abstract: Objective To analyze the effect of adverse drug reactions (ADRs) monitoring by Chinese Hospital Pharmacovigilance System (CHPS), so as to provide reference for ADRs monitoring in Chinese medical institutions. Methods The ADR reports reported one year before and after the application of CHPS in our hospital were selected, and the report situation and the quality of report form in the two periods were statistically analyzed, to evaluate the application effect of CHPS. Results After the application of CHPS, the total number of reports increased from 60 to 174, and the total number of active monitoring reports by pharmacists increased from 25 to 99. The average time for each report was shortened from 35.39mins to 15.77mins, and the rate of unqualified reports decreased from 40.63% to 3.23%. Conclusion The establishment and application of CHPS has effectively improved the level of ADR monitoring and management in hospitals, which is of great significance for further strengthening the pharmacovigilance in Chinese hospitals.

Key words: Chinese hospital pharmacovigilance system, adverse drug reaction

中图分类号:

R994.11

莫凯, 农莉, 曹雯, 钟慧, 王艳宁, 蓝晓步. 基于中国医院药物警戒系统开展药品不良反应监测研究[J]. 中国药物警戒, 2020, 17(10): 672-675.

MO Kai, NONG Li, CAO Wen, ZHONG Hui, WANG Yanning, LAN Xiaobu. Research on Adverse Drug Reaction Monitoring Based on Chinese Hospital Pharmacovigilance System[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 672-675.

参考文献

[1] Wen RL, Li LH, Luo WT, et al.Study on the application effects of ADR rapid reporting system in the hospital[J]. China Pharmacy(中国药房), 2017, 28(20): 2784-2786.
[2] Li JM.Strengthen management and improve the quantity and quality analysis of adverse drug reaction reports[J]. Capital Medicine(首都医药), 2013 (12): 37-39.
[3] Hu WJ, Cai JF.The current situation and existing problems of monitoring adverse reactions caused by drugs in China[J]. Contemporary Medical Symposium(当代医药论丛), 2018, 16(14): 128-129.
[4] Ren LQ.Analysis of adverse drug reaction reports from 2011 to 2013[J]. Chinese Remedies & Clinics(中国药物与临床), 2015, 15(8): 1184-1186.
[5] Shu T, Chen WG, Hou YF, et al.Research and application of the sentinel hospital pharmacovigilance system based on HIS[J]. China Pharmacy(中国药房), 2017, 28(25): 3468-3471.
[6] State Food and Drug Administration. Annual report of national ADR monitoring (2017) [EB/OL]. (2018-04-10)[2019-10-11]. http://www.nmpa.gov.cn/WS04/CL2138/227761.html.
[7] Zhou H, Jin H H, Qin JF, et al.Establishment and Application of Intelligent Reporting System for Adverse Drug Reactions in Hospitals[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(2): 93-97,110.
[8] Wang CH X.Influence of clinical pharmacist intervention on adverse drug reaction monitoring[J]. Medical Journal of Chinese People's Health(中国民康医学), 2019, 31(24): 37-39.
[9] Li X, Yu Q, Guo YM.Application analysis of rapid reporting system of adverse drug reactions in our hospital[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2018, 15(3): 173-176.
[10] Zheng Q, Zheng ZQ, Yang SH, et al.Problems and Countermeasures of ADR monitoring under the new situation of medical reform[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药杂志), 2018, 11(7): 162-164.
[11] Bao HL, Li JF, Wu ZA.Analysis on Influencing Factors of Quality of Adverse Drug Reaction Reports in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(4): 226-229.
[12] Wei He, Difei Yao, Yangmin, Hu, et al.Analysis of a Pharmacist-Led Adverse Drug Event Management Model for Pharmacovigilance in an Academic Medical Center Hospital in China[J]. Ther Clin Risk Manag, 2018(14): 2139-2147.
[13] Zhang XM, Xu MD, Chen WG, et al.Research on National Sentinel Alliance for Adverse Drug Reaction Surveillance Based on CHPS[J]. Chinese Pharmaceutical Affairs(中国药事), 2019, 33(2): 137-142.
[14] Zhou Y, Zhang YJ.Analysis and monitoring of adverse drug reactions[J]. Strait Pharmaceutical Journal(海峡药学), 2019, 31(9): 268-270.
[15] Xinling Li, Haona Li, Jianxiong Deng, et al.Active Pharmacovi- gilance in China: Recent Development and Future Perspectives[J]. Eur J Clin Pharmacol, 2018, 74(7): 863-871.

基于中国医院药物警戒系统开展药品不良反应监测研究

Research on Adverse Drug Reaction Monitoring Based on Chinese Hospital Pharmacovigilance System

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.